Ph.D., 2009, Univ. of California, Berkley
We are interested in dissecting the distinct functions of synaptic cell-adhesion molecules implicated in neuropsychiatric disorders and addiction in the context of disease-relevant brain circuits. Using cutting-edge multidisciplinary techniques,
we are able to interrogate these molecules with cell-type and synapse-specific resolution.
Ph.D., 2009, Columbia University
Molecular Mechanisms of ion channel function. Examining structural and regulatory mechanisms of the Acid-sensing ion channels using electrophysiology, fluorescence, spectroscopy, and structural biology.
Ph.D., 1996, Heinrich-Pette-Institute
Molecular mechanisms of bi-directional synaptic plasticity that underlie cognition. Strategies for restoring normal synaptic plasticity in neurological disorders.
M.D./Ph.D., 1995, Baylor College of Medicine
Mechanisms of synaptic plasticity and impacts of development and epilepsy.
Ph.D., 2008, Univ. of California, Los Angeles
Ph.D., 2010, Univ. de Buenos Aires
Our group aims to understand how mitochondria reprogramming in tumors impact cellular behaviors that drive progressive and lethal cancer. We use a broad repertoire of biochemistry, cell biology, live cell imaging and animal models to study the impact
of mitochondria shape, number and subcellular distribution in metastatic dissemination.
Ph.D., 1987, Johns Hopkins Univ.
Structure and mechanism in gene regulation; biophysical and structural studies of protein-nucleic acid and protein-protein complexes in chromatin and bacterial pathogenesis.
Ph.D., 2009, Indiana Univ.
Systems and network biology approaches to disentangle signaling pathways in cancer development; Computational modeling of how therapeutic compounds function across different genomic backgrounds.
Ph.D., 1992, Univ. of California, Santa Cruz
The molecular dissection of signaling pathways in prostatic cells, the identification of prostate progenitor or stem cells, and understanding epithelial-stromal interactions in normal and abnormal ductal morphogenesis.
Professor and Vice Chairman
Ph.D., 1995, Harvard Univ.
Organization of signaling complexes by protein kinase and phosphatase anchoring proteins; mechanisms regulating neuronal second messenger signaling in synaptic plasticity.
M.D./Ph.D., 2001, Univ. of Pennsylvania
Basic and translational research related to lung cancer.
Ph.D., 1998, Purdue Univ.
Viral protein/host protein interactions, enzyme dynamics, and ligand/receptor interactions involved in cancer progression.
Ph.D., 1996, Univ. of California Los Angeles
Hematopoietic Stem Cell Development and Maintenance: The Role of the "Mixed Lineage Leukemia" Gene in Normal Blood Cell Development, Differentiation and Leukemia.
Ph.D., 1999, Universidad de Buenos Aires
Mechanisms of gene expression control and cancer biology' for 'Mechanisms of gene expression control, cancer biology, Down syndrome.
Ph.D., 2003, Univ. of Alberta
We study the synaptic mechanisms by which neuromodulators like dopamine and acetylcholine are encoded in mesolimbic and nigrostriatal circuits through their G-protein coupled receptors and the alterations that occur in these systems in neurological
and psychiatric diseases.
Ph.D., 1995, Univ. of Rochester
Parallels between normal development and tumorigenesis/metastasis, epithelial to mesenchymal transition, role of homeoproteins and their cofactors in breast, ovarian, and pediatric tumors, particularly in metastatic progression.
M.D., 1969, Harvard Univ.
The dynamic role of dopamine in movement; neural transplantation for Parkinson’s disease.
M.D./Ph.D., 1998, Univ. of Washington
Targeting the glucocorticoid receptor for the treatment of inflammatory disorders of the lung such as asthma.
Ph.D., 1985, Univ. of California, San Diego
Investigating the role of MAP kinases and specific receptor tyrosine kinases in normal and transformed growth of lung epithelial cells using techniques of molecular and cell biology in lung epithelial cells and human lung cancer cell lines.
Ph.D., 1967, Cambridge Univ., UK
Inflammatory process as a paradigm of complex interacting cell networks and communication molecules and as a component of human diseases.
Ph.D., 1999, Univ. of Aberdeen, UK
Basic translational research using neurophysiology, biochemistry, molecular biology, histology and neuro-behavior to elucidate the mechanisms of neuronal injury and identify therapeutic targets for protection and repair.
Ph.D., 1971, Univ. of Alberta
Structure-function studies of multi-protein complexes; de novo design of model proteins to test our understanding of protein folding and structure and to design proteins with the desired biological/immunological activities; synthetic peptide vaccines.
Ph.D., 1974, City Univ. of New York
Neuropharmacology; mechanisms of alcohol tolerance, dependence, and craving; genetic aspects of alcohol dependence and affective disorders; biochemical/molecular biological/genetic analysis of CNS receptors and signal transduction systems.
Ph.D., 1989, Yale Univ.
Computational biology, bioinformatics, gene expression array analysis, natural language processing, biomedical ontologies, machine learning.
Ph.D., 1989, Univ. of Cambridge
Molecular mechanism of alcohols and anesthetic actions; structure and function of biomolecules; NMR spectroscopy, x-ray crystallography, biophysics and molecular biology.
Ph.D., 2003, Univ. of Washington
Molecular mechanisms of activity-triggered synaptic remodeling.
Ph.D., 1997, Univ. of California, Berkeley
The way by which viral RNAs, with their diverse and dynamic structures, can hijack the machinery of an infected cell and using this information to understand basic biological processes.
Ph.D., 1988, Moscow State Univ.
Epigenetics, phosphoinositide signaling, structural biology, NMR and crystal structures of proteins implicated in cancer, structure based drug design.
Ph.D., 1975, Univ. of Georgia
Signal transduction mechanisms regulating phospholipase A2 activation and the production of lipid mediators of inflammation.
Ph.D., 1998, Vanderbilt Univ.
Epigenetic regulation of heart failure; signaling and transcriptional mechanisms of muscle disease.
University Distinguished Professor
Ph.D., 1970, Massachusetts Institute of Technology
Pharmacology and biochemistry of leukotrienes and bioactive lipids, lipid mediators of cellular response using biochemical mass spectrometry.
Ph.D., 1977, Cornell Univ.
Signaling pathways controlling growth and differentiation of vascular smooth muscle cells; Role of eicosanoids in lung cancer.
Chief and Professor
M.D., 1992, Carol Davila Univ. of Medicine and Pharmacy
Alpha 1 antitrypsin biology; Chronic Obstructive Pulmonary Disease (COPD); Lung Cell Biology; Lung Inflammation; Lung Injury and Repair; Pulmonary Vascular Disease; Regenerative Medicine; Sphingolipid signaling and metabolomics; Vascular Biology
Ph.D., 1998, Thomas Jefferson Univ.
The various biological functions regulated by glycogen synthase kinase-3 (Gsk-3) isoforms, and the ketogenic diet, which is used to treat epilepsy in children.
Ph.D., 1989, Univ. of Utah
G-protein linked receptors and their regulation; regulation of mRNA stability.
Ph.D., 1999, Colorado State Univ.
We are interested in the cellular and molecular machinery responsible for cardiac pacemaking and its regulation by the autonomic nervous system.
Ph.D., 1988, Univ. of Washington
Signaling through calcium channels in neurons.
M.D., 2001, Univ. of Pittsburgh
Our laboratory focuses on the mechanisms underlying sepsis and septic organ injury. We are particularly interested in the role of glycosaminoglycans in the onset, propagation, and resolution of septic lung, kidney, and brain injury.
Ph.D., 1996, Univ. of Bremen
Animal Imaging (MRI, PET, CT); Magnetic Resonance Spectroscopy (MRS) based metabonomics; Cancer Metabolism and Physiology; Anti-Cancer Drugs; Ischemia/Reperfusion in Organs.
Ph.D., 1983, Case Western Reserve Univ.
Neurogenomics; disease gene discovery; human genome evolution and variation.
Ph.D., 2011, Univ. of Michigan, Ann Arbor
Steroid hormones; anti-estrogen; breast cancer
Ph.D., 2010, Univ. College London, London, UK
Molecular mechanisms underlying disrupted Excitatory/Inhibitory (E/I) balance and relevance to neuropsychiatric disease.
Ph.D., 2007, Univ. of Texas Southwestern Medical Center
Using stem cells as a tool in the treatment of heart disease.
Ph.D., 1997, Univ. of Pennsylvania/ Univ. Federal do Rio de Janerio
Signal transduction and gene expression in adult and pediatric human heart failure.
Ph.D., 1970, Univ. of Colorado at Boulder
Molecular pharmacology; pharmacogenetics; neuroadaptation and neurotransmitter metabolism/enzymology; CNS receptor molecular pharmacology and genetics/genomics of addiction
Paul A. Bunn, Jr. Endowed Chair in Cancer Research, Professor of Surgery and Pharmacology, Director of the University of Colorado Comprehensive Cancer Center
M.D., 1986, Queen's Univ. Faculty of Health Sciences; Ph.D., 1993, Univ. of Toronto
Working on a disease that has seen few advances in the last 30 years, Theodorescu has emerged as a leading translational bladder cancer researcher. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools
that determine drug response as well as discovery of new drugs for several cancer types.
Professor and Chairman
D.Phil., 1990, Univ. of Oxford
Understanding the signaling mechanisms that control apoptosis in cancer development and during the response of tumor cells to cancer therapeutics.
Ph.D., 1999, Univ. of Washington
Study and manipulation of protein homeostasis and signaling pathways in live cells, optogenetic tools for controlling protein interactions, synthetic biology, cytosolic protein misfolding, yeast genetics/genomics.
M.D., 1979, São Paulo University of Medicine
Overall goals are to define the mechanisms of COPD pathogenesis and the molecular, cellular, and histopathological features of Pulmonary Hypertension. Our lab studies the pathogenesis of cigarette smoke induced emphysema and its underlying mechanisms,
including the role of RTP-801 and adipocytokine, as well as his investigation in the pathogenesis of schistosomiasis-related pulmonary hypertension and development of targeted methods and treatment of pulmonary hypertension.
Ph.D., 1978, Oak Ridge National Laboratory
Phospholipid transport processes in eukaryotic cells. Pulmonary surfactant proteins – structure and function.
M.D., 1984, Beijing Medical Univ.
TGF-beta signal transduction, molecular mechanisms of cancer development and progression, functions of tumor suppressors and oncogenes.
Ph.D., 1992, Colorado State Univ.
Defining the molecular signaling mechanisms regulating vascular smooth muscle cell function in the setting of vascular fibroproliferative diseases, including restenosis and pulmonary hypertension.